UNSPSC 51322703: Pravastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C23H36O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KXO2KT9N0G, chemically known as 1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone but generally known as pravastatin, which bears US NIH Compound Identifier 53232. European Medicines Agency schedules Pravastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10004MIG.

UNSPSC 51322703 Pravastatin, a Commodity code, covers pharmaceutical products acquired by state and local governments for emergency medical services, public health programs, and pharmacy benefit initiatives. State and local buyers under this code are soliciting generic and brand-name medications for immediate operational use—primarily emergency life support drugs, multi-source generics for institutional distribution, and direct-to-manufacturer prescription programs aimed at cost management. Issuing bodies include city fire rescue departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple states and local jurisdictions. The scope of work ranges from supply of individual medication line items for paramedic protocols to large-scale multi-state pharmaceutical contracts requiring manufacturer compliance with FDA, cGMP, and Drug Supply Chain Security Act standards.

Recent activity shows geographic spread across Florida, Texas, and Minnesota-led cooperative arrangements serving Oregon and other allied states. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem vials—a $40,000 contract with a 5 percent SLBE bid discount—due April 8, 2026, with a one-year term and three optional 30-day renewals. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; this exploratory solicitation targets direct contracting relationships outside traditional PBM and GPO channels but carries no budget or timeline at the RFI stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, requiring vendors to work through three authorized wholesalers with pricing weighted 75 percent in evaluation, cGMP and DSCSA compliance mandatory, and two-year initial terms with optional extension through June 30, 2028.